{
    "Clinical Trial ID": "NCT00593827",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone 16 mg/m^2",
        "  ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest",
        "INTERVENTION 2: ",
        "  Ixabepilone 40 mg/m^2",
        "  ixabepilone 40 mg/m^2 every 3 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3)  50",
        "  Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer",
        "  Prior chemotherapy is permitted with no limit on the number of prior regimens",
        "  Two weeks or more have elapsed since last chemotherapy or radiation treatment",
        "  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2",
        "  Is female,  18 yrs of age",
        "  Protocol defined appropriate laboratory values",
        "  Negative pregnancy test within 7 calendar days prior to registration",
        "  Has signed a patient informed consent",
        "Exclusion Criteria:",
        "  Had prior treatment with ixabepilone or other epothilones",
        "  Has HER2+ disease",
        "  Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor \u00ae EL (polyoxyethylated castor oil)",
        "  Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy",
        "  Is receiving concurrent investigational therapy or has received such therapy within the past 30 days",
        "  Has peripheral neuropathy > Grade 1",
        "  Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible",
        "  Is pregnant or breast feeding"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months",
        "  PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.",
        "  Time frame: From the date of randomization to 6-months on study",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone 16 mg/m^2",
        "  Arm/Group Description: ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest",
        "  Overall Number of Participants Analyzed: 85",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  28.6        (18.9 to 38.9)",
        "Results 2: ",
        "  Arm/Group Title: Ixabepilone 40 mg/m^2",
        "  Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks",
        "  Overall Number of Participants Analyzed: 91",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  42.7        (31.5 to 53.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 25/82 (30.49%)",
        "  neutropenia 1/82 (1.22%)",
        "  anemia 1/82 (1.22%)",
        "  thrombocytopenia 1/82 (1.22%)",
        "  febrile neutropenia 0/82 (0.00%)",
        "  tachycardia 3/82 (3.66%)",
        "  fibrillation atrial 0/82 (0.00%)",
        "  supraventricular tachycardia 1/82 (1.22%)",
        "  ventricular tachycardia 1/82 (1.22%)",
        "  angina attack 0/82 (0.00%)",
        "  congestive heart failure 0/82 (0.00%)",
        "  flutter atrial 0/82 (0.00%)",
        "Adverse Events 2:",
        "  Total: 30/89 (33.71%)",
        "  neutropenia 5/89 (5.62%)",
        "  anemia 1/89 (1.12%)",
        "  thrombocytopenia 1/89 (1.12%)",
        "  febrile neutropenia 2/89 (2.25%)",
        "  tachycardia 1/89 (1.12%)",
        "  fibrillation atrial 1/89 (1.12%)",
        "  supraventricular tachycardia 0/89 (0.00%)",
        "  ventricular tachycardia 0/89 (0.00%)",
        "  angina attack 1/89 (1.12%)",
        "  congestive heart failure 1/89 (1.12%)",
        "  flutter atrial 1/89 (1.12%)"
    ]
}